Adult Malignant Glioma Therapeutics Market Global Industry Analysis, Size, Growth, Trends, Share and Forecast 2017 - 2026

Aug 2018| TMR863A| Transparency

Report Highlights

Adult Malignant Glioma Therapeutics Market - Overview

This report studies the current as well as future prospects of the global adult malignant glioma therapeutics market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of malignant glioma therapeutics and new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global adult malignant glioma therapeutics market regarding leading segments based on type, therapy, and region.

The global adult malignant glioma therapeutics market has been segmented based on type, therapy, and region. In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others.

The bottom-up approach for determining the market size was studied using various market indicators obtained from secondary sources, which include population in 2017, prevalence of all types of malignant glioma in major countries, variations in therapy cost across major regions, and approval of therapeutics in specific region. The top-down approach was used to derive the market size for therapy segments, wherein revenues of all publicly listed market players were obtained through secondary sources and analyzed for glioma specific revenues by narrowing down to revenue percentage for product segment through extensive secondary analysis of annual reports, investor presentations, press releases, primary interviews, and others. Data triangulation is based on secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global adult malignant glioma therapeutics market and could influence it in the near future. Market attractiveness analysis has been provided to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global adult malignant glioma therapeutics market. The report also comprises adult malignant glioma disease overview by type, pipeline analysis, Porter’s Five Forces analysis, overview of epidemiology of glioma, snapshot of disease burden by key region / country, SWOT analysis by key therapies, regulatory scenario, reimbursement scenario, comparative analysis of available therapies & imaging landscape, and key market trends by region.

In terms of region, the global adult malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The report also provides market size and forecast for major countries with each product and distribution channel in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the overview section. This section of the report also provides the market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global adult malignant glioma therapeutics market.

Major players operating in the global adult malignant glioma therapeutics market are Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

The global adult malignant glioma therapeutics market has been segmented as follows:

Global Adult Malignant Glioma Therapeutics Market, by Type
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Others

Global Adult Malignant Glioma Therapeutics Market, by Therapy
Chemotherapy
Temozolomide
Bevacizumab
Carmustine
Others
Targeted Drug Therapy
EGFR Inhibitors
Other Monoclonal Antibodies
Others
Radiation Therapy

Global Adult Malignant Glioma Therapeutics Market, by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain


Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand


Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

  • Table 1 : Signatures and Clinical Features of Glioblastoma (GBM) Subtypes
  • Table 2 : Disease Burden, by Key Region/Country (1/2)
  • Table 3 : Disease Burden, by Key Region/Country (2/2)
  • Table 4 : Comparative Analysis of Orphan Drug Policies
  • Table 5 : Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
  • Table 6 : Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
  • Table 7 : Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
  • Table 8 : Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
  • Table 9 : Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 10 : North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 11 : North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
  • Table 12 : North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
  • Table 13 : North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
  • Table 14 : North America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
  • Table 15 : Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 16 : Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
  • Table 17 : Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
  • Table 18 : Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
  • Table 19 : Europe Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
  • Table 20 : Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 21 : Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
  • Table 22 : Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
  • Table 23 : Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
  • Table 24 : Asia Pacific Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
  • Table 25 : Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 26 : Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
  • Table 27 : Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
  • Table 28 : Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
  • Table 29 : Latin America Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
  • Table 30 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 31 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Type, 2016–2026
  • Table 32 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Therapy, 2016–2026
  • Table 33 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Chemotherapy, 2016–2026
  • Table 34 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, by Targeted Drug Therapy, 2016–2026
  • Figure 1 : Global Adult Malignant Glioma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
  • Figure 2 : Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Type (2017)
  • Figure 3 : Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy (2017)
  • Figure 4 : Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Region (2017)
  • Figure 5 : Overall Survival Time of Glioblastoma Patients, by Therapy
  • Figure 6 : Overall Survival Time of Glioblastoma Patients, by Age Group
  • Figure 7 : Glioblastoma Patients Relative Survival Rates
  • Figure 8 : Overall Incidence Rate of Glioma %
  • Figure 9 : Regulatory Approval Process - U.S.
  • Figure 10 : Regulatory Approval Process - Europe
  • Figure 11 : Regulatory Approval Process - Japan
  • Figure 12 : Global Adult Malignant Glioma Therapeutics Market Trends, by Region
  • Figure 13 : Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
  • Figure 14 : Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
  • Figure 15 : Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Glioblastoma Multiforme, 2016–2026
  • Figure 16 : Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Astrocytoma, 2016–2026
  • Figure 17 : Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Oligodendroglioma, 2016–2026
  • Figure 18 : Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anaplastic Oligoastrocytoma, 2016–2026
  • Figure 19 : Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
  • Figure 20 : Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
  • Figure 21 : Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
  • Figure 22 : Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Chemotherapy, 2016–2026
  • Figure 23 : Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Targeted Therapy, 2016–2026
  • Figure 24 : Global Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Radiation Therapy, 2016–2026
  • Figure 25 : Global Adult Malignant Glioma Therapeutics Market Value Share (%), by Region, 2017 and 2026
  • Figure 26 : Global Adult Malignant Glioma Therapeutics Market Attractiveness, by Region, 2018–2026
  • Figure 27 : North America Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 28 : North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Country, 2017 and 2026
  • Figure 29 : North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Country, 2018– 2026
  • Figure 30 : North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
  • Figure 31 : North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
  • Figure 32 : North America Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
  • Figure 33 : North America Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018– 2026
  • Figure 34 : Europe Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 35 : Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 36 : Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 37 : Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
  • Figure 38 : Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
  • Figure 39 : Europe Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
  • Figure 40 : Europe Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
  • Figure 41 : Asia Pacific Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 42 : Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub- region, 2017 and 2026
  • Figure 43 : Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 44 : Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Type 2017 and 2026
  • Figure 45 : Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
  • Figure 46 : Asia Pacific Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy 2017 and 2026
  • Figure 47 : Asia Pacific Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy 2018–2026
  • Figure 48 : Latin America Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 49 : Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub- region, 2017 and 2026
  • Figure 50 : Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub- region, 2018–2026
  • Figure 51 : Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
  • Figure 52 : Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018–2026
  • Figure 53 : Latin America Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
  • Figure 54 : Latin America Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018– 2026
  • Figure 55 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
  • Figure 56 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 57 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 58 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Type, 2017 and 2026
  • Figure 59 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Type, 2018– 2026
  • Figure 60 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Value Share (%), by Therapy, 2017 and 2026
  • Figure 61 : Middle East & Africa Adult Malignant Glioma Therapeutics Market Attractiveness, by Therapy, 2018–2026
  • Figure 62 : Global Adult Malignant Glioma Therapeutics Market Share, by Company, 2017
  • Figure 63 : AbbVie, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 64 : AbbVie, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 65 : AbbVie, Inc. Breakdown of Net Sales, by Drug, 2017
  • Figure 66 : AbbVie, Inc. Research and Development Cost (US$ Mn), 2015–2017
  • Figure 67 : Merck & Co., Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
  • Figure 68 : Merck & Co., Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 69 : Merck & Co., Inc. Breakdown of Net Sales, by Business Segment, 2017
  • Figure 70 : Merck & Co., Inc. Research & Development Cost, 2015–2017 (US$ Bn)
  • Figure 71 : Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 72 : Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
  • Figure 73 : F. Hoffmann-La Roche Ltd Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
  • Figure 74 : F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Region, 2017
  • Figure 75 : F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Business Segment, 2017
  • Figure 76 : F. Hoffmann-La Roche Ltd Research & Development Cost, 2015–2017 (US$ Mn)
  • Figure 77 : Bristol-Myers Squibb Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 78 : Bristol-Myers Squibb Company Breakdown of Net Sales (%), by Region, 2017
  • Figure 79 : Bristol-Myers Squibb Company Breakdown of Net Sales, by Product Segment, 2017
  • Figure 80 : Bristol-Myers Squibb Company Research & Development Cost, 2015–2017 (US$ Mn)
  • Figure 81 : Amgen, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 82 : Amgen, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 83 : Amgen, Inc. Breakdown of Net Sales, by Type of Sale, 2017
  • Figure 84 : Amgen, Inc. Research and Development Cost (US$ Mn), 2015–2017
  • Figure 85 : Sun Pharmaceuticals Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
  • Figure 86 : Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Region, 2017
  • Figure 87 : Sun Pharmaceuticals Ltd. Breakdown of Net Sales, by Product Segment, 2017
  • Figure 88 : Sun Pharmaceuticals Ltd. Research & Development Cost (US$ Mn), 2015–2017
  • Figure 89 : Teva Pharmaceutical Industries Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 90 : Teva Pharmaceutical Industries Limited Breakdown of Net Sales, by Region, 2017
  • Figure 91 : Teva Pharmaceutical Industries Limited Breakdown of Net Sales, by Business Segment, 2017
  • Figure 92 : Teva Pharmaceutical Industries Limited Research and Development Cost (US$ Mn), 2015–2017

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report